AU742535B2 - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions Download PDF

Info

Publication number
AU742535B2
AU742535B2 AU75448/98A AU7544898A AU742535B2 AU 742535 B2 AU742535 B2 AU 742535B2 AU 75448/98 A AU75448/98 A AU 75448/98A AU 7544898 A AU7544898 A AU 7544898A AU 742535 B2 AU742535 B2 AU 742535B2
Authority
AU
Australia
Prior art keywords
composition
sertraline
matter
solubilising agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU75448/98A
Other languages
English (en)
Other versions
AU7544898A (en
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU742535(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU7544898A publication Critical patent/AU7544898A/en
Application granted granted Critical
Publication of AU742535B2 publication Critical patent/AU742535B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
AU75448/98A 1997-07-01 1998-06-15 Solubilized sertraline compositions Ceased AU742535B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
US60/051413 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (2)

Publication Number Publication Date
AU7544898A AU7544898A (en) 1999-01-25
AU742535B2 true AU742535B2 (en) 2002-01-03

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75448/98A Ceased AU742535B2 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (id)
JP (1) JP2000514100A (id)
KR (1) KR100366373B1 (id)
CN (1) CN1261794A (id)
AP (1) AP1192A (id)
AR (3) AR015917A1 (id)
AU (1) AU742535B2 (id)
BG (1) BG103918A (id)
BR (1) BR9810739A (id)
CA (1) CA2290974C (id)
CO (1) CO4940495A1 (id)
DZ (1) DZ2548A1 (id)
EA (1) EA002481B1 (id)
HN (1) HN1998000102A (id)
HR (1) HRP980377A2 (id)
HU (1) HUP0002236A3 (id)
ID (1) ID23429A (id)
IL (1) IL133076A (id)
IS (1) IS5260A (id)
MA (1) MA24587A1 (id)
NO (1) NO996520L (id)
OA (1) OA11243A (id)
PA (1) PA8454301A1 (id)
PE (1) PE97199A1 (id)
PL (1) PL337804A1 (id)
SK (1) SK181099A3 (id)
TN (1) TNSN98124A1 (id)
TR (1) TR199903297T2 (id)
TW (1) TW550087B (id)
UA (1) UA67741C2 (id)
UY (1) UY25071A1 (id)
WO (1) WO1999001120A1 (id)
YU (1) YU68299A (id)
ZA (1) ZA985708B (id)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
WO2008110268A1 (en) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Cosmetic compositions
WO2011081117A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用固形医薬組成物
KR20120116422A (ko) * 2009-12-29 2012-10-22 코와 가부시키가이샤 경구 투여용 의약 조성물
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612A2 (en) * 1989-08-30 1991-03-06 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612A2 (en) * 1989-08-30 1991-03-06 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies

Also Published As

Publication number Publication date
EA002481B1 (ru) 2002-06-27
UY25071A1 (es) 2000-12-29
SK181099A3 (en) 2000-07-11
AP9801280A0 (en) 1998-06-30
KR20010013365A (ko) 2001-02-26
DZ2548A1 (fr) 2003-02-08
HN1998000102A (es) 1999-01-08
MA24587A1 (fr) 1998-12-31
TR199903297T2 (xx) 2000-07-21
EP0999829A1 (en) 2000-05-17
IL133076A (en) 2003-12-10
CA2290974A1 (en) 1999-01-14
YU68299A (sh) 2002-06-19
CA2290974C (en) 2004-04-27
CN1261794A (zh) 2000-08-02
IL133076A0 (en) 2001-03-19
HUP0002236A2 (hu) 2003-08-28
EA199900962A1 (ru) 2000-08-28
WO1999001120A1 (en) 1999-01-14
IS5260A (is) 1999-11-19
AR040279A2 (es) 2005-03-23
CO4940495A1 (es) 2000-07-24
AR040280A2 (es) 2005-03-23
PA8454301A1 (es) 2000-09-29
OA11243A (en) 2003-07-24
AU7544898A (en) 1999-01-25
HRP980377A2 (en) 1999-04-30
BG103918A (en) 2000-07-31
AR015917A1 (es) 2001-05-30
AP1192A (en) 2003-07-23
HUP0002236A3 (en) 2003-12-29
NO996520D0 (no) 1999-12-28
UA67741C2 (uk) 2004-07-15
PE97199A1 (es) 1999-10-05
PL337804A1 (en) 2000-09-11
JP2000514100A (ja) 2000-10-24
KR100366373B1 (ko) 2003-01-14
ID23429A (id) 2000-04-20
TNSN98124A1 (fr) 2005-03-15
BR9810739A (pt) 2000-09-12
TW550087B (en) 2003-09-01
NO996520L (no) 2000-02-29
ZA985708B (en) 2000-01-10

Similar Documents

Publication Publication Date Title
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
US5527545A (en) Liquid-suspension controlled-release pharmaceutical composition
JP2774080B2 (ja) 医薬組成物
JP4072597B2 (ja) 持続性製剤
Yadav et al. Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation
KR20010012857A (ko) 개선된 약물 전달용 위장체류 방출조절 미소립자
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
SK180499A3 (en) Sertraline salts and sustained-release dosage forms of sertraline
JPH10511112A (ja) ダリフェナシン含有製剤
SK8252001A3 (en) Controlled release formulation of divalproex sodium
CN102238946A (zh) 用于哌醋甲酯的控制释放的药物组合物
JP2005532289A (ja) 持続放出性医薬製剤及びその製造方法
TW575437B (en) Delayed-release dosage forms of sertraline
AU742535B2 (en) Solubilized sertraline compositions
WO2020157730A1 (en) A controlled release pharmaceutical composition of selexipag or it's active metabolite
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
JPH0748256A (ja) ニセルゴリンを含有する制御放出性の製薬組成物
US20040208926A1 (en) Solubilized sertraline compositions
NZ501250A (en) Solubilized sertraline compositions
BR112021012259A2 (pt) Composição farmacêutica contendo hidrocloreto de tansulosina com excelente resistência a ácidos e método de preparação da mesma
Pagay Use of buffers in matrix capsule formulations
Parida et al. Optimization, In-Vitro and In-Vivo Evaluation of Floating Tablet of Tetrabenazine
CZ464199A3 (cs) Solubilizované sertralinové kompozice
MXPA99012101A (en) Solubilized sertraline compositions
KR950007097B1 (ko) 서방성 캡슐

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)